tiprankstipranks
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
PremiumPress ReleasesIntellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
20d ago
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
23d ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
1M ago
5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024
PremiumMarket News5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024
3M ago
Intellia Expands At-The-Market Offering Program with Jefferies
PremiumCompany Announcements
Intellia Expands At-The-Market Offering Program with Jefferies
3M ago
Intellia Therapeutics downgraded to Neutral from Buy at Goldman Sachs
PremiumThe Fly
Intellia Therapeutics downgraded to Neutral from Buy at Goldman Sachs
3M ago
Intellia Therapeutics price target lowered to $24 from $38 at Baird
PremiumThe FlyIntellia Therapeutics price target lowered to $24 from $38 at Baird
3M ago
Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF
PremiumThe Fly
Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF
3M ago
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
PremiumPress Releases
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100